Delmer Dee Raibourn III
@Avidity Partners Management Lp
Latest period2024 - Q3ReportedManaged Assets$1.96BTotal holdings81
Assets growth rate-16.7%Assets growth rate (2-Q avg)-20.41%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Avidity Partners Management Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 81 positions.
Assets under management
The assets under management (AUM) of Avidity Partners Management Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.96B in assets, with a quarterly growth rate of -16.7% and a 2-quarter average growth rate of -20.41%. The portfolio is managed by Delmer Dee Raibourn III, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
AZNAstrazeneca Plc
| 0% | $15.988M 205,000 shares@ $77.99 avg price | Exited |
CRBPCorbus Pharmaceuticals Hldgs
| 0% | $9.756M 215,600 shares@ $45.25 avg price | Exited |
CYBNCybin Inc
| 0% | $9.454M 34.884M shares@ $0.28 avg price | Exited |
TYRATyra Biosciences Inc
| 0% | $5.964M 373,000 shares@ $15.99 avg price | Exited |
PATHUipath Inc
| 0% | $4.59M 362,000 shares@ $12.68 avg price | Exited |
SYRESpyre Therapeutics Inc
| 0% | $4.584M 195,000 shares@ $23.51 avg price | Exited |
IMTXImmatics N.v
| 0% | $4.568M 393,100 shares@ $11.62 avg price | Exited |
IONSIonis Pharmaceuticals Inc
| 0% | $4.432M 93,000 shares@ $47.66 avg price | Exited |
ABIOArca Biopharma Inc
| 0% | $3.83M 1M shares@ $3.83 avg price | Exited |
NTLAIntellia Therapeutics Inc
| 0% | $3.805M 170,000 shares@ $22.38 avg price | Exited |